Clinical Trial

Clinical Trial to Evaluate the Tolerance of TQB2210 Injection

Completed Phase 1
View on ClinicalTrials.gov →
Summary
TQB2210 injection is a humanized monoclonal antibody against FGFR2b, which can bind to FGFR2b with high specificity and inhibit tumor growth by blocking the signaling pathway mediated by fibroblast growth factor receptor. The aim of this experiment is to evaluate the tolerability, pharmacokinetics, and preliminary efficacy of TQB2210 injection in patients with advanced malignant tumors, and to assess its effectiveness and phase II recommended dose (RP2D) in advanced malignant tumors with FGFR2b overexpression, such as advanced gastric/gastroesophageal junction cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-14; most recent amendment 2026-04-13.
Status change: Recruiting → Completed 2026-04-13
Status change: Not Yet Recruiting → Recruiting 2025-05-19
Trial Details
NCT Number NCT06929195
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Conditions Advanced Malignant Tumours
Enrollment 16 participants
Start Date 2025-05-16
Primary Completion 2026-04-10 (estimated)
Study Completion 2026-04-10 (estimated)
Updated on ClinicalTrials.gov 2026-04-14